Practice Areas - Equity Capital Markets Law Firms and Lawyers
| Deal Date: | 08-07-2020 | Practice Area: | Equity Capital Markets |
| Deal Title: | Shenzhen Hepalink Pharmaceutical HKSE Initial Public Offering | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HKD4.05 billion (USD523 million) prior to any exercise of the over-allotment option.
|
||
| Financial Center: | Hong Kong | Value: | 500.01-1000.00 |
| Advised Party: | Issuer | Law Firm | Davis Polk |
| Issuer Jurisdiction- | China | Listing Jurisdiction- | Hong Kong |
| Classification: |
Initial Public Offerings Hong Kong Stock Exchange |
Lawyer | Li He |
